Hytest’s patent portfolio consists of several patents relating to diagnostics of cardiovascular diseases. For further information and inquiries regarding patent licensing, please contact us by writing to:

Immunoassay Kit for Quantification of BNP and proBNP  

The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex. 


Detection of Cardiac Muscle Necrosis by immunoassay and Appropriate Antibodies thereof

This invention relates to clinical diagnostics and more particularly to the diagnostics and therapy follow-up of heart muscle necrosis. The invention concerns with a new approach to monitor the condition of heart by leakage of two proteins, troponin I and C, from necrotic heart muscle.


Stable Standards for BNP Immunoassays

This invention relates to BNP antigen, and particularly to use of a new stable from of said antigen as a standard or calibrator in immunoassays measuring BNP immunoreactivity.


Quantification of an Unstable Antigen Selected from BNP and proBNP

This invention relates to immunoassays, and provides an immunoassay method for detection of unstable antigens. The method is specifically suitable for detection of BNP, proBNP and fragments thereof.


Detection of IGFBP-4 Fragments as a Diagnostic Method

This invention describes a method for diagnosing of cardiovascular diseases, which comprises detection of IGFBP-4 (insulin- like growth factor binding protein-4) fragments in patients’ blood. It provides antibodies as well as epitopes for antibodies, specific to proteolytic fragments (both N- and C-terminal) of IGFBP-4 originated from IGFBP-4 molecule after its cleavage by specific protease PAPP-A. Antibodies could be used for development of immunoassay methods for quantitative or qualitative detection of IGFBP-4 fragments in human blood.


Method for Determining the Risk of Cardiovascular Events Using IGFBP Fragments

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE). 


HYTEST® and  undefined ® are registered trademarks of Hytest Oy in the USA and other countries.

Do you need samples?

We are happy to make you an offer